Status:
COMPLETED
Extension to the MAGNIFY MS Trial on Mavenclad® (Magnify MS Extension)
Lead Sponsor:
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Conditions:
Multiple Sclerosis
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
The primary purpose of this study was to evaluate the long-term effectiveness of Mavenclad® tablets, in terms of disease activity and safety, in participants with highly-active relapsing multiple scle...
Eligibility Criteria
Inclusion
- Participants of the MAGNIFY Multiple Sclerosis (MS) trial who received at least a single dose of cladribine tablets during the MAGNIFY MS trial and data on Magnetic resonance imaging (MRI) is available/acquired from at least parent study Month 18 or Month 24 visit and Expanded Disability Status Scale (EDSS) and relapse from parent study Month 24 visit
- Capable of giving signed informed consent
Exclusion
- Participant is considered by the Investigator, for any reason, to be an unsuitable candidate for the study
- Participation in other studies/trials
Key Trial Info
Start Date :
March 10 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 21 2023
Estimated Enrollment :
219 Patients enrolled
Trial Details
Trial ID
NCT04783935
Start Date
March 10 2021
End Date
September 21 2023
Last Update
January 22 2025
Active Locations (46)
Enter a location and click search to find clinical trials sorted by distance.
1
Liverpool Hospital
Liverpool, Australia
2
John Hunter Hospital
New Lambton, Australia
3
Klinikum Klagenfurt
Klagenfurt, Austria
4
Paracelsus Medical University Salzburg
Salzburg, Austria